Compare AbCellera Biologics Inc (ABCL) vs Cipher Mining Inc (CIFR) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

CIFR trades at $21.73, up 8.43% today but remains in a bearish technical trend. The company is transitioning from Bitcoin mining to AI data center operations, with $11.4B in contracted lease revenue from AWS and Fluidstack. Despite strong analyst support (13 buy ratings), fundamentals show deep losses with -427.79% net margin and negative cash flow from operations.

The investment case hinges on successful execution of the AI infrastructure pivot, with revenue expected to ramp from 2027. Key risks include high valuation multiples, negative profitability, and execution challenges in data center deployment. The consensus price target of $31.61 suggests 45% upside if the transition succeeds.